# Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

Study · id `cardio:ct-nct03001076` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03001076](<https://clinicaltrials.gov/study/NCT03001076>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03001076

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 269 participants.

## Technical summary

Registry record NCT03001076. Randomized; triple masking; primary purpose treatment. Start 2016-11-29 (actual); primary completion 2018-01-11 (actual). Results posted on 2020-04-03.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 269 participants (enrolled count; ClinicalTrials.gov record NCT03001076, source copy `cardio:ctgov-nct03001076-2020-05-11`, retrieved 2026-10-31)
- Started: 2016-11-29 (actual) (ClinicalTrials.gov record NCT03001076, source copy `cardio:ctgov-nct03001076-2020-05-11`, retrieved 2026-10-31)
- Primary completion: 2018-01-11 (actual) (ClinicalTrials.gov record NCT03001076, source copy `cardio:ctgov-nct03001076-2020-05-11`, retrieved 2026-10-31)
- Completion: 2018-02-12 (actual) (ClinicalTrials.gov record NCT03001076, source copy `cardio:ctgov-nct03001076-2020-05-11`, retrieved 2026-10-31)
- Results first posted: 2020-04-03 (ClinicalTrials.gov record NCT03001076, source copy `cardio:ctgov-nct03001076-2020-05-11`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT03001076, source copy `cardio:ctgov-nct03001076-2020-05-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03001076-2020-05-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
- Condition: Hypercholesterolemia
- Condition: Atherosclerosis
- Condition: Statin Adverse Reaction
- Intervention (Drug): Bempedoic acid
- Intervention (Drug): Ezetimibe
- Intervention (Other): Placebo
- Lead sponsor: Esperion Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Bempedoic acid (`cardio:bempedoic-acid`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry lists this organization as the lead sponsor: Esperion Therapeutics, Inc. (`cardio:org-esperion-therapeutics-inc`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study (`cardio:pubmed-29910030`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: eed13b5d98f487035995e272c44918413aedc1ba430ee884bbd4f114377b88d4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
